Prediction of concurrent chemoradiotherapy efficacy and its related molecular signaling pathway by medical artificial intelligence model based on CT of lung cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100053175

Enrollment

Unknown

Registered

2021-11-13

Start date

2021-12-01

Completion date

Unknown

Last updated

2022-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Gold Standard:RECIST 1.1 evaluation based on repeat CT 3 months after treatment.

Index test:AI-based&#32

forecasting&#32

system

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with non-small cell lung cancer diagnosed by pathology; 2. No other local or systemic treatment (surgical resection, microwave ablation or oral targeted drugs) before the first chemoradiotherapy; 3. According to TNM staging standard, it is divided into IIIA-C stage; 4. PS score <= 2; 5. Availability of standard chest dynamic contrast-enhanced CT images at baseline and follow-up.

Exclusion criteria

Exclusion criteria: 1. Combined with other malignant solid tumors; 2. Insufficient CT raw data or incomplete CT data; 3. Follow-up data are incomplete.

Design outcomes

Primary

Measure	Time frame
objective response rate;accuracy;specificity;	—

Countries

China

Contacts

Public ContactPeng Jie

The Second Affiliated Hospital of Guizhou Medical University

sank44@sina.com+86 13648553774

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026